Collagen-induced arthritis in mice: A major role for tumor necrosis factor-α

Methods in Molecular Biology

Volumn 361, Issue , 2007, Pages 265-284

  Williams, Richard O ^a  

^a NONE

Author keywords

Autoimmunity; Collagen induced arthritis; Experimental animal models; Rheumatoid arthritis; TNF ; Type II collagen

Indexed keywords

ANIMALIA; MUS; RATTUS;

COLLAGEN TYPE 2; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ANIMAL; ARTHRITIS; B LYMPHOCYTE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GENE; IMMUNOLOGY; MOUSE; PATHOLOGY; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CLINICAL TRIALS; COLLAGEN TYPE II; CYTOKINES; GENES, MHC CLASS II; MICE; T-LYMPHOCYTES;

EID: 35748938527     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-208-4:265     Document Type: Article

References (72)

1. Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum. 36, 1681-1690.
2. Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Treatment with a chimeric monoclonal antibody to tumour necrosis factor a suppresses disease activity in rheumatoid arthritis: results of a multi-centre, randomised, double blind trial. Lancet 344, 1105-1110.
3. Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Repeated therapy with a monoclonal antibody to tumour necrosis factor a in patients with rheumatoid arthritis. Lancet 344, 1125-1127.
4. Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl. J. Med. 337, 141-147.
5. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259.
6. Kempeni, J. (1999) Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. Ann. Rheum. Dis. 58, 170-172.
7. den Breeder, A., van de Putte, L., Rau, R., et al. (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) inpatients with rheumatoid arthritis. J. Rheumatol. 29,2288-2298.
8. Weinblatt, M. E., Keystone, E. C., Furst, D. E., et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45.
9. Williams, R. O. (1998) Rodent models of arthritis: relevance for human disease. Clin. Exp. Immunol. 114, 330-332.
10. Ranges, G. E., Sriram, S., and Cooper, S. M. (1985) Prevention of type II collageninduced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162, 1105-1110.
11. Horn, J. T., Butler, L. D., Riedl, P. E., and Bendele, A. M. (1988) The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur. J. Immunol. 18, 881-888.
12. Webb, L. M., Walmsley, M. J., and Feldmann, M. (1996) Prevention and amelioratrion of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26, 2320-2328.
13. Malfait, A. -M., Butler, D. M., Presky, D. H., Maini, R. N., Brennan, F. M., and Feldmann, M. (1998) Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. Ill, 377-383.
14. Holmdahl, R., Andersson, M. E., Goldschmidt, T. J., et al. (1989) Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS 97, 575-584.
15. Trentham, D. E. (1982) Collagen arthritis as a relevant model for rheumatoid arthritis: evidence pro and con. Arthritis Rheum. 25, 911-916.
16. Williams, R. O., Williams, D. G., and Maini, R. N. (1992) Anti-type II collagen ELISA. Increased disease specificity following removal of anionic contaminants from salt-fractionated type II collagen. J. Immunol. Methods 147, 93-100.
17. Marinova-Mutafchieva, L., Williams, R. O., Mason, L. J., Mauri, C., Feldmann, M., and Maini, R. N. (1997) Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 107, 507-512.
18. Hegen, M., Sun, L., Uozumi, N., et al. (2003) Cytosolic phospholipase A2alphadeficient mice are resistant to collagen-induced arthritis. J. Exp. Med. 197, 1297-1302.
19. Holmdahl, R., Jansson, L., Larsson, E., Rubin, K., and Klareskog, L. (1986) Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum. 29, 106-113.
20. Boissier, M. C., Feng, X. Z., Carlioz, A., Roudier, R., and Fournier, C. (1987) Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann. Rheum. Dis. 46, 691-700.
21. Malfait, A. M., Williams, R. O., Malik, A. S., Maini, R. N., and Feldmann, M. (2001) Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 44, 1215-1224.
22. Huang, J. C., Vestberg, M., Ming-ela, A., Holmdahl, R., and Ward, E. S. (2004) Analysis of autoreactive T cells associated with murine collagen-induced arthritis using peptide-MHC multimers. Int. Immunol. 16, 283-293.
23. Keffer, J., Probert, L., Cazlaris, H., et al. (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031.
24. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F., and Kollias, G. (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398.
25. Probert, L., Plows, D., Kontogeorgos, G., and Kollias, G. (1995) The type I interleukin1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-ttansgenic mice. Eur. J. Immunol. 25, 1794-1797.
26. Brennan, F. M., Chantry, D., Jackson, A., Maini, R., and Feldmann, M. (1989) Inhibitory effect of TNFa antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1, 244-247.
27. Niki, Y., Yamada, H., Seki, S., et al. (2001) Macrophage- and neuttophil-dominant arthritis in human IL-I alpha transgenic mice. J. Clin. Invest. 107, 1127-1135.
28. Fell, H. B. and Jubb, R. W. (1977) The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum. 20, 1359-1371.
29. Saklatvala, J., Pilsworth, L. M., Sarsfield, S. J., Gavrilovic, J., and Heath, J. K. (1984) Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem. J. 224, 461-466.
30. Saklatvala, J., Sarsfield, S. J., and Townsend, Y. (1985) Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J. Exp. Med. 162, 1208-1222.
31. Mclntyre, K. W, Shuster, D. J., Gillooly, K. M., et al. (1996) Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur. J. Immunol. 26, 2933-2938.
32. Wei, X. Q1, Leung, B. P., Arthur, H. M., McInnes, I. B., and Liew, F. Y. (2001) Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. 166, 517-521.
33. Plater-Zyberk, C., Joosten, L. A., Helsen, M. M., et al. (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 108, 1825-1832.
34. Alonzi, T., Fattori, E., Lazzaro, D., et al. (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468.
35. Sasai, M., Saeki, Y., Ohshima, S., et al. (1999) Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42, 1635-1643.
36. Takagi, N., Mihara, M., Moriya, Y., et al. (1998) Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41, 2117-2121.
37. Mihara, M., Kotoh, M., Nishimoto, N., et al. (2001) Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol. 98, 319-326.
38. Nakae, S., Nambu, A., Sudo, K., and Iwakura, Y. (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171, 6173-6177.
39. Lubberts, E., Joosten, L. A., Oppers, B., et al. (2001) IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J. Immunol. 167, 1004-1013.
40. Lubberts, E., Koenders, M. I., Oppers-Walgreen, B., et al. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collageninduced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650-659.
41. Lawlor, K. E., Campbell, I. K., Metcalf, D., et al. (2004) Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc. Natl. Acad. Sci. USA 101, 11,398-11,403.
42. Cuzzocrea, S., Mazzon, E., Dugo, L., et al. (2001) Absence of endogeneous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur. Cytokine Netw. 12, 568-580.
43. Johansson, A. C., Hansson, A. S., Nandakumar, K. S., Backlund, J., and Holmdahl, R. (2001) IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J. Immunol. 167, 3505-3512.
44. Walmsley, M., Katsikis, P. D., Abney, E., et al. (1996) IL-10 inhibits progression of established collagen-induced arthritis. Arthritis Rheum. 39, 495-503.
45. Mauri, C., Williams, R. O., Walmsley, M., and Feldmann, M. (1996) Relationship between Thl/Th2 cytokine patterns and the arthritogenic response in collageninduced arthritis. Eur. J. Immunol. 26, 1511-1518.
46. Vermeire, K., Heremans, H., Vandeputte, M., Huang, S., Billiau, A., and Matthys, P. (1997) Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 158, 5507-5513.
47. Manoury-Schwartz, B., Chiocchia, G., Bessis, N., et al. (1997) High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. Immunol. 158, 5501-5506.
48. Williams, R. O., Williams, D. G., Feldmann, M., and Maini, R. N. (1993) Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin. Exp. Immunol. 92, 323-327.
49. Boissier, M. C., Chiocchia, G., Bessis, N., et al. (1995) Biphasic effect of interferongamma in murine collagen-induced arthritis. Eur. J. Immunol. 25, 1184-1190.
50. Brennan, F. M., Zachariae, C. O., Chantry, D., et al. (1990) Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur. J. Immunol. 20, 2141-2144.
51. Alvaro-Garcia, J. M., Zvaifler, N. J., Brown, C. B., Kaushansky, L., and Firestein, G. S. (1991) Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-I and TNFa. J. Immunol. 146, 3365-3371.
52. Butler, D. M., Maini, R. N., Feldmann, M., and Brennan, F. M. (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 6, 225-230.
53. Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M., and Palladino, M. A. (1992) Involvement of endogenous tumor necrosis factor a and transforming growth factor ß during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89, 7375-7379.
54. Williams, R. O., Feldmann, M., and Maini, R. N. (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784-9788.
55. Piguet, P. F., Grau, G. E., Vesin, C., Loetscher, H., Gentz, R., and Lesslauer, W. (1992) Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 11, 510-514.
56. Sheehan, K. C., Ruddle, N. H., and Schreiber, R. D. (1989) Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 142, 3884-3893.
57. Wooley, P. H., Dutcher, J., Widmer, M. B., and Gillis, S. (1993) Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151, 6602-6607.
58. Williams, R. O., Ghrayeb, J., Feldmann, M., and Maini, R. N. (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84, 433-439.
59. Issekutz, A. C., Meager, A., Otterness, I., and Issekutz, T. B. (1994) The role of tumour necrosis factor-alpha and IL-I in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin. Exp. Immunol. 97, 26-32.
60. Van den Berg, W. B., Joosten, L. A., Helsen, M., and van de Loo, F. A. (1994) Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237-243.
61. Joosten, L. A. B., Helen, M. M. A., van de Loo, F. A. J., and Van den Berg, W. B. (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFa, anti-TNF/α, and IL-IRa. Arthritis Rheum. 39, 797-809.
62. Lewthwaite, J., Blake, S., Hardingham, T., et al. (1995) Role of TNFa in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies. Ann. Rheum. Dis. 54, 366-374.
63. van de Loo, F. A., Joosten, L. A., van Lent, P. L., Arntz, O. J., and Van den Berg, W. B. (1995) Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 38, 164-172.
64. Kuiper, S., Joosten, L. A., Bendele, A. M., et al. (1998) Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 10, 690-702.
65. Geiger, T., Towbin, H., Cosenti-Vargas, A., et al. (1993) Neutralization of interleukin-1ß activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. 11, 515-522.
66. Bendele, A., McAbee, T., Sennello, G., Frazier, J., Chlipala, E., and McCabe, D. (1999) Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 42, 498-506.
67. Bessis, N., Guery, L., Mantovani, A., et al. (2000) The type II decoy receptor of IL-I inhibits murine collagen-induced arthritis. Eur. J. Immunol. 30, 867-875.
68. Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204.
69. Williams, R. O., Marinova-Mutafchieva, L., Feldmann, M., and Maini, R. N. (2000) Evaluation of TNFa and IL-I blockade in collagen-induced arthritis and comparison with combined anti-TNFa/anti-CD4 therapy. J. Immunol. 165, 7240-7245.
70. Miller, E. J. (1972) Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. Biochemistry 11,4903-4909.
71. Herbage, D., Bouillet, J., and Bernengo, J. C. (1977) Biochemical and physiochemical characterization of pepsin-solubilized type-II collagen from bovine articular cartilage. Biochem. J. 161, 303-312.
72. Ratcliffe, A., Doherty, M., Maini, R. N., and Hardingham, T. E. (1988) Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann. Rheum. Dis. 47, 826-832.